Evidence map›Paper›PMID 38000561›Full record

ArticleJournal of pain and symptom management2024

Ketamine for Pain in Sickle Cell Disease Reduces Opioid Usage.

Christina O Onyebuchi, Corrie E Chumpitazi, Jennifer L Placencia, Andrea N Jackson, Jennifer L Jones, Laura Torres, Venée N Tubman

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pain and symptom management, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07682662 (Evaluation of a Standardized Low-Dose Bolus Ketamine Pathway for Management of Pediatric Sickle Cell Patients Presenting to the Emergency Department With Pain), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07682662 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluation of a Standardized Low-Dose Bolus Ketamine Pathway for Management of Pediatric Sickle Cell Patients Presenting to the Emergency Department With Pain

TypeinterventionalSponsorUniversity of Mississippi Medical CenterRan2026 to 2029Enrolled400ConditionsVaso-Occlusive Pain Episode in Sickle Cell Disease, Sickle Cell Disease (SCD)ArmsStandardized Low-dose bolus IV Ketamine within 30 minutes of arrival and every 1 hour as needed for max of 3 doses., Standard Care (in control arm)
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Christina O OnyebuchiUniversity of Texas Medical Branch (C.O.), Galveston, Texas, USA.
Corrie E ChumpitaziDepartment of Pediatrics, Division of Emergency Medicine (C.C., J.L.), Baylor College of Medicine, Houston, Texas, USA; Texas Children's Hospital (C.C., J.P., A.J.), Houston, Texas, USA.
Jennifer L PlacenciaTexas Children's Hospital (C.C., J.P., A.J.), Houston, Texas, USA.
Andrea N JacksonTexas Children's Hospital (C.C., J.P., A.J.), Houston, Texas, USA.
Jennifer L JonesDepartment of Pediatrics, Division of Emergency Medicine (C.C., J.L.), Baylor College of Medicine, Houston, Texas, USA.
Laura TorresDeparment of Anesthesiology (L.T.), Baylor College of Medicine, Houston, Texas, USA.
Venée N TubmanDepartment of Pediatrics (V.T.), Baylor College of Medicine, Houston, Texas, USA; Texas Children's Cancer and Hematology Centers (V.T.), Houston, Texas, USA. Electronic address: vntubman@txch.org.
Texas Children's Hospital · USBaylor College of Medicine · USChildren's Cancer Center · USThe University of Texas Medical Branch at Galveston · US

Funding

Characterization of B Lymphocyte Deficiency in Pediatric Sickle Cell DiseaseK23HL148548 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI TUBMAN, VENEE N · 2020 to 2024
$816k
NHLBI NIH HHS K23 HL148548
6 · The paper itself

Abstract

contextPain attributable to sickle cell disease (SCD) is often unpredictable, recurrent, and requires complex treatments. Subanesthetic ketamine infusion has been studied in other diseases and disorders, but there is still limited data on its efficacy in pain management for SCD.

objectivesThe primary objective is to determine if subanesthetic ketamine infusion reduces pain scores and opioid requirements in hospitalized pediatric patients with SCD.

resultsForty-six admissions among 22 patients between February 2018 and December 2019 were analyzed. We observed decrease in pain scores within 24 hours of ketamine initiation in 34 of 46 admissions (mean pain score per patient before ketamine initiation: 2.2-9.7, mean pain score per patient after ketamine initiation: 0-9.7; P < .05). We observed a decrease in pain scores in the remaining 12 admissions after greater than 24 hours of ketamine initiation. Opioid usage declined after ketamine infusion, with a difference of means in oral morphine equivalents before and after ketamine of 122.8 mg/day. The side effects observed with ketamine infusion included hallucinations in 11 (23.9%) admissions. Only four (8.7%) admissions required cessation of the infusion due to side effects. The readmission rate at two weeks and four weeks after first ketamine infusion was the same (12.5%) at both time points. For all patients in the cohort, the introduction of ketamine into pain regimens did not reduce the number of admissions in the year following ketamine initiation relative to the year prior.

conclusionIn pediatric patients with SCD, subanesthetic ketamine was safe as a continuous infusion and effectively reduced both pain scores and opioid requirements.

Indexed as

Anemia, Sickle CellKetamineAnalgesicsAnalgesics, OpioidChildHumansMorphinePainAnalgesicsAnalgesics, OpioidKetamineMorphineopioid-sparing analgesiapediatricssickle cell diseaseSubanesthetic ketaminevaso-occlusive episode

Identifiers

PMID38000561
PMCPMC11061893
OpenAlexW4388924156

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.